(1 - 11 von 14
)
Signs that Amgen bone drug may block breast tumours - Reuters
www.reuters.com
"Further studies will be needed to prove the principle of our findings," said Daniel Schramek, who worked on the research with Josef Penninger at the Institute of Molecular Biotechnology in Vienna. "But we hope that medical trials using denosumab can be started in the near future to test whether the mouse ...
IMBA director Josef Penninger receives Wittgenstein Award 2014www.lisavienna.at › news › imba-director-josef-penninger-receives-wittgen...
www.lisavienna.at
· The Austrian federal government has named Josef Penninger, the scientific director at the IMBA - Institute of Molecular Biotechnology at the ...
APEIRON Biologics announces financing round for the ...
www.bionity.com
APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO ... more. Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi. Evotec …
APEIRON: New CEO announced - bionity.com
www.bionity.com
· APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO to Peter Llewellyn-Davies (60), the former Chief Financial and Business …
sortiert nach Relevanz / Datum